Viatris uses a comprehensive strategy to help address antimicrobial resistance (AMR). This includes expanding access to more than 90 antimicrobial products and working closely with partners such as the AMR …
Antimicrobial resistance (AMR) poses a major global health threat, affecting millions of people worldwide and potentially causing even greater disruptions to healthcare if left unaddressed. AMR undermines the effectiveness of …
Noncommunicable diseases (NCDs) are the world’s leading cause of death, creating an immense strain on individuals, healthcare systems, and economies. Every year, around 18 million people die prematurely—before reaching 70—from …
In 2024, Viatris supplied medications targeting the top ten causes of death worldwide, as identified by the WHO. The company has deliberately focused on expanding access to its diverse portfolio …
As Leo stands in his office, overseeing the entrance of Viatris’ dynamic workspace in the Netherlands, he reflects on the five decades that have defined his career. From his early …
Viatris is dedicated to achieving a 42% reduction in absolute scope 1 and 2 greenhouse gas (GHG) emissions, along with a 25% decrease in absolute scope 3 GHG emissions, all …
Viatris is actively seeking methods to decrease the volume and variety of materials utilized in packaging while ensuring access to high-quality medicines and adhering to regulatory and quality standards globally. …
The production and use of pharmaceuticals, as well as the well-being of communities and patients, hinge on the supply of clean, uncontaminated water. Our operations strive to promote responsible water …
In 2022, Viatris collaborated with our long-term partner, Direct Relief, to provide critical medicines to people affected by Ukraine’s ongoing crisis. “You stepped up in a major way – extraordinarily …
